The Efficacy of Alfuzosin for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle Aged Patients.
10.4111/kju.2007.48.8.858
- Author:
Young Guen RYU
1
;
Hyung Jee KIM
;
Heung Jae PARK
Author Information
1. Department of Urology, Dankook University College of Medicine, Cheonan, Korea. killtumor@yahoo.co.kr
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Prostate;
Alpha blocker;
Pain
- MeSH:
Humans;
Male;
Middle Aged*;
Pelvic Pain*;
Prostate;
Prostatic Hyperplasia;
Prostatitis
- From:Korean Journal of Urology
2007;48(8):858-862
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Many studies about efficacy of alpha blocker to Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) have shown variable results. The aim of this study was to confirm the efficacy of alpha blocker in young and middle aged patients with CP/CPPS to exclude the effect of benign prostatic hyperplasia. MATERIALS AND METHODS: Fifty seven men with CP/CPPS were randomized in a single-blind fashion, to receive either; tosufloxacin(450mg/d)(group 1; 15 patients), or; tosufloxacin(450mg/d) and alfuzosin(10mg/d)(group 2; 42 patients) for 2 months. The NIH chronic prostatitis symptom index (NIH-CPSI), International Prostate Symptom Score(IPSS) and International Index of Erectile Function-5(IIEF-5) were used to grade the symptoms and the quality of life(QoL) impact at the start and 1 and 2 months into the study. RESULTS: There was no significant difference between group 1 and group 2 in relation to age, duration and sub-factor scores of IPSS, NIH-CPSI and IIEF-5 at the baseline. No statistically significant difference in the NIH- CPSI total score was seen, but the urinary and QoL factors in group 2 showed greater improvement. A statistically significant difference was seen in the IPSS total score, especially, obstructive factor in group 2 showed greater improvement. The IIEF-5 total score was seen more increase, but it wasn't significant. CONCLUSIONS: The efficacy of alfuzosin demonstrated improvements in the NIH-CPSI(this was not significant.) and IPSS total score. Especially voiding factors were significantly improved in relation to the NIH-CPSI and IPSS scores in the alfuzosin treatment group.
